ClinicalTrials.gg
RecruitingNCT07857616Updated Nov 4, 2026

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of SI-B036 in Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors and Metastatic Solid Cancers, sponsored by SystImmune Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
424
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd. — 16 open to participants now, 27 under way, 9 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sichuan Biokin Pharmaceutical Co., Ltd..

Planned enrollment
8th of 28
424 · median 93
Started
2026
with 6 others
Phase 1
9 of 28
6 open now
Primary completion
2028-10
later than 19 of 26 live
Registered
28th of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd., this one is the 8th largest by planned enrollment, is one of 7 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 19 of the 26 other live ones, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 28 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd. are open now, in 6 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.

Read the detailed description

This study is an open-label, multicenter, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of SI-B036 in participants with locally advanced or metastatic solid tumors.

03

Conditions studied

  • Locally Advanced /Metastatic Solid Tumors
  • Locally Advanced / Metastatic Solid Tumors
  • Metastatic Solid Cancers
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • Melanoma
  • Ovarian
  • NSCLC

Keywords

  • PD-L1
  • VEGFR-2
  • First in Human
  • FIH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented locally advanced or solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standard therapy, including /neoadjuvant treatment, or whose cancer is considered to the standard of care (SOC) or for which no standard treatment is available.
  • Toxicity of previous antitumor therapy has returned to level ≤1 as defined by National Cancer Institute (NCI) (CTCAE) V6.0.
  • Has no serious cardiac dysfunction and ≥50%.
  • Has adequate organ function before enrollment

PART C Additional Inclusion Criteria (Dose Expansion Only)

- For immuno-oncology (IO)-exposed non-small cell lung cancer (NSCLC): or cytologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in subjects who are previously exposed to (ICI) therapy (IO-exposed) and whose disease is refractory to standard of care (SOC) therapy or for whom no appropriate standard treatment options are available. In addition, subjects must have received at least one prior line of platinum therapy.

For IO naïve NSCLC: histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC in subjects who are not previously exposed to ICI therapy. Subjects must also have PD-L1 expression ≥1% (tumor proportion score [TPS]) as determined by an FDA-approved assay. In addition, subjects must have received at least one prior line of platinum therapy.

For Melanoma: histologically confirmed unresectable or metastatic melanoma with prior treatment with an immune checkpoint inhibitor regimen and documented disease progression following such therapy.

For Ovarian Cancer: has histologic documentation of epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed on or after a previous chemotherapy with or without a poly (ADP-ribose) polymerase (PARP) inhibitor. Prior bevacizumab treatment is allowed.

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy, biological therapy, immunotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; radical radiotherapy, major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral drugs such as Ticio such as capecitabine, or palliative radiotherapy within 2 weeks prior to initial administration.
  • Received systemic immunostimulatory therapy within 4 weeks prior to the first dose or is still within 5 half-lives of the treatment (whichever is longer).
  • Received drugs within 2 weeks prior to the first dose. The use of topical, inhaled, and locally injected is permitted.
  • Participants with history of severe heart disease within 6 months before enrollment.
  • Participants with prolonged (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block, or a history of additional risk factors for Torsades de Pointes (TdP) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP.
  • Other malignant tumors were diagnosed within 5 years prior to the first administration.
  • For the dose escalation portion of the study only, participants with a primary diagnosis of lung cancer are excluded.
  • Participants with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]), stroke, or (TIA) within 6 months before screening.
  • Participants with active or recent bleeding are excluded, or who are at risk of bleeding due to clinically significant abnormalities or coagulopathy, or who require full-dose anticoagulation or high-intensity antiplatelet therapy on high dose nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Active diseases and inflammatory diseases. For autoimmune conditions that are active but stable and low-grade on systemic therapy, discussion with the medical monitor is required prior to screening.
  • Participants with advanced/clinically significant lung diseases, who have a history of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening, or concurrent pulmonary disease resulting in severe impaired respiratory function.
  • Participants with primary tumors in the central nervous system (CNS), active or untreated or carcinomatous meningitis should be excluded. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to Screening.
  • Participant with active or untreated hemorrhagic CNS lesions.
  • Participants with a history of anaphylaxis or severe reactions.
  • Previous organ transplantation or hematopoietic stem cell transplantation.
  • Subjects with recent surgery, , or invasive procedures without adequate wound healing prior to study enrollment.
  • Participated in another clinical trial within 4 weeks prior to first dose of study treatment.
  • Participants who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • History of fistula, gastrointestinal perforation, or abdominal abscess within 6 months prior to the first dose.
  • Participant with moderate or major hemoptysis history.
  • Participant has tumors invading large blood vessels
  • Other conditions that the Investigator or sponsor believes are not suitable for participating in this clinical trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
424 participants (estimated)

Study arms

  • Experimental
    Experimental SI-B036 administered Day 1 per cycle

    SI-B036 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

    Drug: SI-B036

Interventions

  • SI-B036 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

06

What researchers measure

Primary outcomes

  1. Participants with Dose-Limiting Toxicities

    A DLT is defined as any of the following: * Grade 4 neutrophil count decreased lasting \>7 days. * Grade ≥3 febrile neutropenia of any duration. * Grade ≥3 platelet count decreased with clinically significant hemorrhage. * Grade 4 thrombocytopenia lasting \>72 hours * Death not related to disease progression or extraneous cause. * Hy's law cases * Grade ≥3 infusion-related reactions (IRRs) leading to permanent discontinuation * Grade ≥3 non-hematologic toxicities, except for: * Grade 3 nausea/vomiting or diarrhea for \<72 hours with adequate antiemetic and other supportive care; * Grade 3 fatigue for less than 1 week; * Grade ≥3 electrolyte abnormality that lasts up to 72 hours, is not clinically complicated, and resolves spontaneously or responds to conventional medical interventions; * Grade ≥3 amylase or lipase that is not associated with symptoms or clinical manifestations of pancreatitis and does not require hospitalization

    Time frame: 24 months

  2. Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)

    Measuring the number of patients with serious adverse events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)

    Time frame: 24 months

  3. Participants with abnormal physical examination findings

    Measure the number of participants with abnormal physical examination findings.

    Time frame: 24 months

  4. Participants with abnormal lab results

    Measure the number of participants with abnormal clinical laboratory values

    Time frame: 24 months

  5. Participants with abnormal ECG reading

    Patients with abnormal ECG parameters (including the change from-baseline ECG parameters: heart rate \[HR\]; PR; QTcF; and QRS intervals \[∆HR, ∆PR, ∆QTcF, and ∆QRS\])

    Time frame: 24 months

  6. To determine the maximum tolerated dose (MTD) if reached or minimum safe and pharmacologically effective dose (MSED).

    The actual number of subjects enrolled and dose levels to be explored in this study will depend on the MTD and/or MSED based on DLTs reported during the DLT observation period.

    Time frame: 24 months

Secondary outcomes

  1. Cmax of SI-B036

    Calculate maximum (peak) observed concentration of SI-B036

    Time frame: 24 months

  2. Cmax of anti-drug antibodies (ADAs) to SI-B036

    Calculate maximum (peak) observed concentration of anti-SI-B036 antibodies

    Time frame: 24 months

  3. Tmax of SI-B036

    Calculate time of maximum observed concentration of SI-B036

    Time frame: 24 months

  4. Tmax of anti-SI-B036 antibodies

    Calculate time of maximum observed concentration of anti-SI-B036 antibodies

    Time frame: 24 months

  5. AUC(0-8) of SI-B036

    Calculate area under the serum concentration-time curve of SI-B036 from time 0 to 8 hours

    Time frame: 24 months

  6. AUC(0-8) of anti-SI-B036 antibodies

    Calculate area under the serum concentration-time curve of anti-SI-B036 antibodies from time 0 to 8 hours

    Time frame: 24 months

  7. AUC(last) of SI-B036

    Calculate area under the serum concentration-time curve up of SI-B036 to the last quantifiable time (0 to 8 hours)

    Time frame: 24 months

  8. AUC(last) of anti-SI-B036 antibodies

    Calculate area under the serum concentration-time curve up of anti-SI-B036 antibodies to the last quantifiable time (0 to 8 hours)

    Time frame: 24 months

  9. Overall Response Rate (ORR)

    To assess the clinical efficacy of SI-B036 as measured by ORR using RECIST criteria v1.1

    Time frame: 24 months

  10. Disease Control Rate (DCR)

    To assess the clinical efficacy of SI-B036 as measured by DCR using RECIST criteria v 1.1

    Time frame: 24 months

  11. Time To Response (TTR)

    To assess the clinical efficacy of SI-B036 as measured by TTR using RECIST criteria v 1.1

    Time frame: 24 months

  12. Progression-Free Survival (PFS)

    To assess the clinical efficacy of SI-B036 as measured by PFS using RECIST criteria v 1.1

    Time frame: 24 months

  13. Overall Survival (OS)

    To assess the clinical efficacy of SI-B036 as measured by OS using RECIST criteria v 1.1

    Time frame: 24 months

  14. Duration of response (DoR)

    To assess the clinical efficacy of SI-B036 as measured by DoR using RECIST criteria v 1.1

    Time frame: 24 months

07

Study locations

4 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 5, 2026
StartActual
Jul 30, 2026was Sep 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
7 sites changed recruiting status (4 now recruiting, 3 now not yet recruiting)
Show 7 sites
  • Yale Cancer Center · New Haven, United Statesno status→Not yet recruiting
  • Florida Cancer Specialists Lake Nona · Orlando, United Statesno status→Recruiting
  • Florida Cancer Specialists Sarasota · Sarasota, United Statesno status→Recruiting
  • OU Health Stephenson Cancer Center · Oklahoma City, United Statesno status→Not yet recruiting
  • Sarah Cannon Research Institute - Oncology Partners · Nashville, United Statesno status→Recruiting
  • Mary Crowley Cancer Research · Dallas, United Statesno status→Recruiting
  • MD Anderson · Houston, United Statesno status→Not yet recruiting
Nov 4, 2026
Start date
Sep 2026→Jul 30, 2026 (actual)
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • MD Anderson · Houston, United StatesContact •••6558→none listed
Oct 28, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    7 sites changed recruiting status (4 now recruiting, 3 now not yet recruiting)
    Show 7 sites
    • Yale Cancer Center · New Haven, United Statesno status→Not yet recruiting
    • Florida Cancer Specialists Lake Nona · Orlando, United Statesno status→Recruiting
    • Florida Cancer Specialists Sarasota · Sarasota, United Statesno status→Recruiting
    • OU Health Stephenson Cancer Center · Oklahoma City, United Statesno status→Not yet recruiting
    • Sarah Cannon Research Institute - Oncology Partners · Nashville, United Statesno status→Recruiting
    • Mary Crowley Cancer Research · Dallas, United Statesno status→Recruiting
    • MD Anderson · Houston, United Statesno status→Not yet recruiting
    Start date Sep 2026→Jul 30, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 28, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MD Anderson · Houston, United StatesContact •••6558→none listed
    + 1 other change: verification date
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857616
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Jul 30, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Stephanie Yee
Contact
stephanie.yee@systimmune.com
425-453-6841

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SI-B036

Start the discussion